Analysis: Gilbert Cisneros's sell of RVTY (Revvity, Inc.)

Assessment: Low signal

Routine, advisor-managed trimming of a long-held position, executed as a same-day swap into NXPI, with no committee connection or non-public catalysts.

Member: Gilbert Cisneros
Party / state: Democratic-CA
Chamber: House
Transaction: Sell
Amount: $15,001 - $50,000
Ticker: RVTY
Company: Revvity, Inc.
Trade date: 2026-09-09
Disclosure date: 2026-10-12
Disclosure lag: 33 days

Executive summary

Research identified the traded asset as Revvity, Inc. (NYSE: RVTY; CIK 0000031791), with a member-reported sale on 2026-09-09 and disclosure on 2026-10-12 (33-day lag). Primary-source context located includes Revvity’s 2025 Form 10-K (filed 2026-02-24) discussing FDA regulation and government-entity sales/contract compliance risk, one company 8-K filed 2026-08-04 reporting Q2 2026 results and a definitive agreement to divest a China immunodiagnostics business, and Federal Register items in 2026 related to FDA medical device classification/exemptions referencing PerkinElmer/related device categories.

Within the member’s user-provided RVTY trading history (10 total transactions), the 2026-09-09 sale occurred after two smaller RVTY sales on 2026-09-03 and 2026-09-04, and was paired with a same-day purchase of NXPI. Primary-source company disclosures in the broader window include an 8-K filed 2026-08-04 with an attached earnings press release stating Revvity entered a definitive agreement to divest its China Immunodiagnostics business and raised full-year guidance. Federal Register documents in 2026 include an FDA order (published 2026-06-11) classifying an SMA newborn screening test system (referencing a PerkinElmer De Novo request) and an FDA order (published 2026-10-06) exempting certain class II clinical toxicology test systems from 510(k) requirements. USAspending recipient profiles show federal award activity for Revvity-related entities (e.g., 'REVVITY HEALTH SCIENCES, INC.'), including obligations attributed to agencies such as HHS and DOD per the profile page, and at least one example DOD maintenance/repair services contract record. Due to a web-search tool result cap encountered during this run, systematic extraction of all Congress.gov legislative/committee activity in the specified windows, full USAspending award lists near the trade date, Regulations.gov open dockets, and contemporaneous news coverage could not be completed.

Timeline

2026-06-11 — FDA published order classifying the Spinal Muscular Atrophy newborn screening test system into class II; document references PerkinElmer Inc.'s De Novo request (Eonis SCID-SMA Kit).
2026-08-04 — Revvity filed Form 8-K (Items 2.02, 8.01, 9.01) reporting Q2 2026 financial results and attaching press release; press release text includes: entered into definitive agreement to divest China Immunodiagnostics business and raised full-year guidance.
2026-09-03 — Member sold RVTY ($1,001-$15,000) per user-provided trading history.
2026-09-04 — Member sold RVTY ($1,001-$15,000) per user-provided trading history.
2026-09-09 — TRADE UNDER ANALYSIS: Member sold RVTY ($15,001-$50,000) per user-provided trading history.
2026-09-09 — Same-day trade: Member purchased NXPI ($15,001-$50,000) per user-provided trading history.
2026-09-07 — Congress.gov committee schedule week of Sep 7-13, 2026 shows '0 Meetings' for that week (no meeting data listed for Sep 9, 2026).
2026-09-16 — Form 4: insider sale by Tajinder S Vohra (code S) at $140.88/share.
2026-09-21 — Form 4: insider sale by Maxwell Krakowiak (code S) at $144.53/share.
2026-10-01 — Form 4: insider sale by Anita Gonzales (code S) at $155.48/share.
2026-10-06 — FDA published final order exempting certain class II clinical toxicology test systems from 510(k) requirements (subject to limitations).
2026-10-12 — Member filed disclosure reporting the 2026-09-09 RVTY sale (per user-provided trade metadata).

Independent analysis of public financial disclosures. Not financial or investment advice.

Sources

Gilbert Cisneros · RVTY · Trading news